Secondary Logo

April 2019 - Volume 30 - Issue 4

  • Mels Sluyser, PhD
  • 0959-4973
  • 1473-5741
  • 10 / year
  • 181 of 217 Oncology
    187 of 256 Pharmacology & Pharmacy
  • 1.869

Current Issue Highlights



A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Bischoff, Joachim; Barinoff, Jana; Mundhenke, Christoph; More

Anti-Cancer Drugs. 30(4):394-401, April 2019.